FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3114143979> ?p ?o ?g. }

• W3114143979 endingPage "54" @default.
• W3114143979 startingPage "41" @default.
• W3114143979 abstract "Introduction. Arterial Hypertension is the most common disease of the circulatory system. Today we can talk about it as a non-infectious epidemic. Obesity is a risk factor and a frequent comorbid condition in hypertension. The aim. Given the role of dopamine metabolism as one of the pathogenetic triggers of hypertension and obesity, to study the effect of a dopamine receptor agonist bromocriptine in this category of patients. Materials and methods. We examined 111 hypertensive patients with concomitant obesity and 18 hypertensive patients without obesity with dopamine (DA) metabolism disorders. 24 patients with concomitant obesity received the dopamine receptor agonist bromocriptine and the calcium antagonist amlodipine to correct their DA metabolism disorders. The level of DA was determined according to the daily excretion of DA in the urine by fluorometric method. Determination of angiotensin II (ATII) was performed using enzyme-linked immunosorbent assay. The concentration of lipids was determined using the enzymatic colorimetric method, blood pressure was assessed using Daily Monitoring of Blood Pressure (ABPM), the condition of the endothelium was determined using D.S Celermajer’s endothelium-dependent vasodilation assessment. Results. Concomitant obesity leads to a deeper impairment in the dopaminergic system, RAAS, lipid spectrum and endothelial status. Bromocriptine and amlodipine treatment resulted in a significant increase in urinary DA excretion by 1.77 times (77.4%) and a trend towards blood ATII increase, which confirms the assumption of similar mechanism of action of dopamine agonists and angiotensin II receptor antagonist; positivization of lipid spectrum parameters: significant reduction of total cholesterol by 5.7%, TG by 14.01%, LDL by 5.5%. Regarding other lipid metabolism, such as HDL, there was a trend towards increase by 4.6%, combined with a significant improvement in endothelium-dependent vasodilation by 54.8%, lower blood pressure and a positive modulating effect of the combination of these drugs on the daily blood pressure profile against the background of a significant decrease in body weight by 8.8%." @default.
• W3114143979 created "2021-01-05" @default.
• W3114143979 creator A5004622115 @default.
• W3114143979 creator A5022149190 @default.
• W3114143979 creator A5044482569 @default.
• W3114143979 creator A5047799814 @default.
• W3114143979 date "2020-01-01" @default.
• W3114143979 modified "2023-09-27" @default.
• W3114143979 title "Features of Treatment of Hypertensive Patients with Concomitant Obesity: Unknown about the Known" @default.
• W3114143979 doi "https://doi.org/10.30702/card:sp.2020.10.039/0404154" @default.
• W3114143979 hasPublicationYear "2020" @default.
• W3114143979 type Work @default.
• W3114143979 sameAs 3114143979 @default.
• W3114143979 citedByCount "0" @default.
• W3114143979 crossrefType "journal-article" @default.
• W3114143979 hasAuthorship W3114143979A5004622115 @default.
• W3114143979 hasAuthorship W3114143979A5022149190 @default.
• W3114143979 hasAuthorship W3114143979A5044482569 @default.
• W3114143979 hasAuthorship W3114143979A5047799814 @default.
• W3114143979 hasBestOaLocation W31141439791 @default.
• W3114143979 hasConcept C126322002 @default.
• W3114143979 hasConcept C134018914 @default.
• W3114143979 hasConcept C137183658 @default.
• W3114143979 hasConcept C2776856834 @default.
• W3114143979 hasConcept C2777097880 @default.
• W3114143979 hasConcept C2778258207 @default.
• W3114143979 hasConcept C2779064019 @default.
• W3114143979 hasConcept C2779384505 @default.
• W3114143979 hasConcept C2780972559 @default.
• W3114143979 hasConcept C513476851 @default.
• W3114143979 hasConcept C71315377 @default.
• W3114143979 hasConcept C71924100 @default.
• W3114143979 hasConcept C84393581 @default.
• W3114143979 hasConceptScore W3114143979C126322002 @default.
• W3114143979 hasConceptScore W3114143979C134018914 @default.
• W3114143979 hasConceptScore W3114143979C137183658 @default.
• W3114143979 hasConceptScore W3114143979C2776856834 @default.
• W3114143979 hasConceptScore W3114143979C2777097880 @default.
• W3114143979 hasConceptScore W3114143979C2778258207 @default.
• W3114143979 hasConceptScore W3114143979C2779064019 @default.
• W3114143979 hasConceptScore W3114143979C2779384505 @default.
• W3114143979 hasConceptScore W3114143979C2780972559 @default.
• W3114143979 hasConceptScore W3114143979C513476851 @default.
• W3114143979 hasConceptScore W3114143979C71315377 @default.
• W3114143979 hasConceptScore W3114143979C71924100 @default.
• W3114143979 hasConceptScore W3114143979C84393581 @default.
• W3114143979 hasIssue "1 (39)" @default.
• W3114143979 hasLocation W31141439791 @default.
• W3114143979 hasOpenAccess W3114143979 @default.
• W3114143979 hasPrimaryLocation W31141439791 @default.
• W3114143979 hasRelatedWork W1985786391 @default.
• W3114143979 hasRelatedWork W1995049737 @default.
• W3114143979 hasRelatedWork W1998709691 @default.
• W3114143979 hasRelatedWork W2006136814 @default.
• W3114143979 hasRelatedWork W2019937176 @default.
• W3114143979 hasRelatedWork W2040855145 @default.
• W3114143979 hasRelatedWork W2079101059 @default.
• W3114143979 hasRelatedWork W2080277814 @default.
• W3114143979 hasRelatedWork W2105916581 @default.
• W3114143979 hasRelatedWork W2169359703 @default.
• W3114143979 isParatext "false" @default.
• W3114143979 isRetracted "false" @default.
• W3114143979 magId "3114143979" @default.
• W3114143979 workType "article" @default.